Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

IMPORTANCE: The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. OBJECTIVE: To evaluate the efficacy and safety of inotuzumab ozogamicin pl...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Jabbour, Elias, Ravandi, Farhad, Kebriaei, Partow, Huang, Xuelin, Short, Nicholas J., Thomas, Deborah, Sasaki, Koji, Rytting, Michael, Jain, Nitin, Konopleva, Marina, Garcia-Manero, Guillermo, Champlin, Richard, Marin, David, Kadia, Tapan, Cortes, Jorge, Estrov, Zeev, Takahashi, Koichi, Patel, Yogin, Khouri, Maria R., Jacob, Jovitta, Garris, Rebecca, O’Brien, Susan, Kantarjian, Hagop
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2017
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838597/
https://ncbi.nlm.nih.gov/pubmed/28859185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2380
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi